Scientific Program
Scientific program
Wednesday 30th November
13:45 - 14:00 : Opening ceremony
Nadine HOUEDE, Scientific director of Cancéropôle Grand Sud-Ouest
14:00 - 14:40 :
- Opening session
Chairs: Pierre CORDELIER & Claude SARDET
- KEYNOTE SPEAKER Manuel SERRANO, Institute for Research in Biomedicine (Barcelona, Spain) - Understanding and manipulating cellular reprogramming in vivo
14:40 - 16:00 : Plenary session
- New insights in cell death control
Chairs: Pierre CORDELIER & Claude SARDET
- KEYNOTE SPEAKER Pedro FRIEDMANN ANGELI, Rudolf Virchow Zentrum, University of Würzburg (Germany) - Metabolic control of Membrane Redox State: A Matter of Life and Death
- Alexandre DAVID, Institute of Functional Genomics (IGF), Montpellier - The aminoglycoside streptomycin triggers mitochondria-dependant ferroptotic cell death of tumor initiating cells
17:00 - 18:30 : Parallel sessions organized by Cancéropôle GSO Axes
- Nuclear bodies & phase separation in cancer / Axis 1 & Axis 2 session
Chair: Guillaume BOSSIS and Fabian ERDEL
- KEYNOTE SPEAKER Valérie LALLEMAND-BREITENBACH, Centre Interdisciplinaire de Recherche en Biologie du Collège de France, Paris - PML bodies, from leukemia cure to biophysics insight
- Jihane BASBOUS, Institude of Human Genetics (IGH), Montpellier - TopBP1 condensation: a targetable molecular switch in the ATR signaling pathway
- Fernando MUZZOPAPPA, Centre for Integrative Biology of Toulouse (CBI), Toulouse - Identifying phase separation in nuclear compartmentalization
- Liliana KRASINSKA, Institute of Molecular Genetics of Montpellier (IGMM), Montpellier - The cell cycle as a phase separation cycle controlled by protein phosphorylation
- Translational research, from biology to the clinic : Flash Posters / Axis 3 session
Chairs: Marlène DUFRESNE & Fabrice LALLOUE
- EMERGENT PROJECT :
- Aurore DANIGO, University of Limoges - Blockade of CCK2R prevents the onset of vincristine-induced sensory neuropathy in mice
- FLASH POSTERS :
- Marine BRUCIAMACCHIE, Montpellier Cancer Research Institute (IRCM) - Synergistic effect of FOLFIRINOX with an ATR inhibitor on pancreatic tumor cells and its microenvironment -
- Boutaîna CHANDOURI-FAIZE, Control of cell Activation in Tumor Progression and Therapeutic Resistance (CAPTuR), Limoges - Cancer Stem Cell glycosylation markers: A promising biomarker for prognosis and disease progression
- Jean DESCARPENTRIE, Bordeaux Institute of Oncology - Role of Furin in Colon Cancer Stem Cells Phenotype in KRAS and BRAF-Mutated Colon Tumors
- Amandine DESETTE, Poitiers University - Biological and molecular characterization of cancer stem cells in brain metastases from colorectal cancer
- Pénélope DESROYS DU ROURE, Montpellier Cancer Research Institute (IRCM) - Therapeutic efficiency of Fc-engineered human anti-cathepsin D antibody in mono and combotherapy in triple negative breast cancer
- Alexandra FAUVRE, Montpellier Cancer Research Institute (IRCM) - Platinum-based chemotherapy induce inflammation via a non-canonical STING pathway independent on cGAS and interferon production
- Alexia FRANCOIS, Bordeaux Institute of Oncology - Repression of protein maturation inhibits PD-1 expression and enhances tumor clearance and TILS : virtual ligand screening and drug repurposing approach
- Elsa FRISTOT, Structural Biology Center (CBS), Montpellier - Programming lactic acid bacteria for cancer therapy
- Tinhinan LAHLOU, Institute for Functionals Genomics (IGF), Montpellier - Unravelling the role of early dissemination in colorectal cancer
- Chloé PORCHERON, Bordeaux Institute of Oncology - Sensitization of pancreatic cancer to radiotherapy and chemotherapy by proprotein convertase inhibition -
- Zeinab TARHINI, Control of cell Activation in Tumor Progression and Therapeutic Resistance (CAPTuR), Limoges - The Effect of Benzodiazepine and Benzodiazepine-related Drugs on Survival after Surgery for Colorectal Cancer
- Marie BOUTAUD, Control of cell Activation in Tumor Progression and Therapeutic Resistance (CAPTuR), Limoges - Evaluation of a Metformin treatment on CRC cell lines and on a patients’ cohort exhibiting different stages
- Health technologies / Axis 5 session
Chair: Anne-Marie GUE
- IMAGING CANCER
- Elisabeth BELLARD, Institute of Pharmacology and Structural Biology (IPBS), Toulouse - How intravital microscopy helps us to study cancer events
- Dounia EL HAMRANI, IHU Liryc, Bordeaux - Combination of MRI-guided HIFU, bioluminescence imaging and transgenic mouse model to assess efficiency of noninvasive thermal therapies for solid tumors and their microenvironments
- Selected talks for "Ma techno en 180 secondes" (flash posters toutes technologies)
- Chloé BESSIERE, Cancer Research Center of Toulouse (CRCT), Toulouse - TranSipedia: a novel framework for large scale RNAseq data analysis with applications in cancer from research to diagnosis
- Pawan KUMAR, Laboratory of Pathogen Host Interactions (LPHI), Montpellier - Estimating spatial distribution of oxygen and hypoxia in tumor microenvironment: a mechanistic approach
- Florian COGONI, Informatics Research Institute of Toulouse (IRIT), Toulouse - Involving the biologists in the design of in silico models
- Chloé ROYET, Institut des "Biomolécules Max Mousseron" (IBMM), Montpellier - Fluorescent Peptide Biosensors Reporters of Kinase Activities: profiling signatures in human tumour biopsies through a multiplex approach for cancer diagnostics
Thursday 1st December
08:30 - 10:00 : Plenary session
- Heterogeneity & single cell
Chair: Julie PANNEQUIN & Mary POUPOT
- KEYNOTE SPEAKER Céline VALLOT, Curie Institute (Paris) - Epigenomic evolution of breast cancers in response to treatment
- Emeline BOET, Cancer Research Center of Toulouse (CRCT), Toulouse - Drug persisters arise from transcriptionally and mitochondrially distinct stem cell subpopulations in acute myeloid leukemia
- Julie GIRAUD, University of Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux - TREM1+ CD163+ myeloid cells are potent immunosuppressive cells and associate with poor survival in human liver cancer
- Ghita CHABAB, Montpellier Cancer Research Institute (IRCM), Montpellier - Regulatory gamma delta T cells in solid cancer : characterisation, role and ecosystem
- Juan-Pablo CERAPIO-ARROYO, Cancer Research Center of Toulouse (CRCT), Toulouse - Single-cell transcriptomics for a better understanding of tumor infiltrating heterogeneity
11:00 - 12:45 : Plenary session
- Innovations in intracellular targetting
Chairs: Sébastien BRITTON & Anthony MARTIN
- KEYNOTE SPEAKER Alessandro CIULLI, School of Life Sciences, University of Dundee (United Kingdom) - Targeted Protein Degradation as a Cancer Therapeutic Modality
- Eric TRINQUET, Perkin Elmer (Codolet) - The use of the HTRF and AlphaLISA technologies to support compounds identification and characterization in Targeted-Protein Degradation
- Krzysztof ROGOWSKI, Institude of Human Genetics (IGH), Montpellier - Targeting microtubule detyrosination activity of VASOHBINS as a new therapeutic approach for cancer and neurodegeneration
- Francesco CALZAFERRI, Institute des "Biomolécules Max Mousseron" (IBMM), Montpellier - Novel strategies to study epigenetic mechanisms in cancer
- Nicolas BERY, Cancer Research Center of Toulouse (CRCT), Toulouse - Targeting hard-to-drug oncoproteins with intracellular antibodies
14:00 - 14:30 :
- Afternoon Opening
Chair: Hervé SEITZ
- KEYNOTE SPEAKER Gregory HANNON, Cambridge Institute, Cancer Research United Kingdom - FOXC2 promotes vascular mimicry and resistance to anti-angiogenic therapy
14:30 - 16:00 : Parallel sessions organized by Cancéropôle GSO Axes
- Genome Dynamics & Cancer / Axis 2 session
Chair: Jean-Christophe ANDRAU & Eric JULIEN
- Pierre CORDELIER, Cancer Research Center of Toulouse (CRCT), Toulouse - Cytidine deaminase controls replicative stress and protects cancer cells from DNA-targeting drugs
- Bérengère PRADET-BALADE, Centre for Biochemical and Macromolecular Research (CRBM), Montpellier - Targeting RUVBL1/2 chaperones in colorectal cancer
- Cyril ESNAULT, Institute of Molecular Genetics of Montpellier (IGMM), Montpellier - Mechanical regulation of bivalent gene expression via the nuclear lamina
- Claire VARGAS, Cancer Research Center of Toulouse (CRCT), Toulouse - The E3 ubiquitin ligase TRIP12 induces the formation of heterochromatin altering gene expression and DNA damage repair independently of its catalytic activity
- KEYNOTE SPEAKER Gregory HANNON, Cambridge Institute, Cancer Research United Kingdom - A small RNA-based innate immune system guards the integrity of germ cell genomes
- NanoCancer, new devices for therapy / Axis 3 & Axis 5 session
Chairs: Véronique GIGOUX & Olivier SANDRE
- KEYNOTE SPEAKER Géraldine LE DUC, NH TherAguiX (Meylan) - From workbench to Phase 2 clinical trials : development of the nanodrug candidate AGuIX - history and perspectives
- Yannick CREMILLIEUX, Institute of Molecular Sciences (ISM), Bordeaux - Where, when et how many: MRI for theranostic AguiX nanoparticles
- Marie MORILLE, Institute Charles Gerhardt (ICGM), Montpellier - Pharmaceutical development to enhance small Extracellular Vesicles (sEV) therapeutic potential
- Loubna LAIB, Cancer Research Center of Tououse (CRCT), Toulouse - Targeted thermal or mechanical nanotherapy of pancreatic adenocarcinoma
- Nouveaux dispositifs numériques de prévention / session Axe 4 diapositives
Modération: Cyrille DELPIERRE
- Florence COUSSON-GELIE, centre Epidaure et laboratoire Epsylon, Montpellier - Epidaure Market, évaluation de l’efficacité et de la transférabilité d’une intervention en milieu scolaire visant à améliorer les choix alimentaires équilibrés et durables chez des collégiens
- Claire LAFAY-CHEBASSIER, Université de Poitiers et CHU de Poitiers, Etudes pilotes multi-méthodes évaluant l’intérêt d’une intervention musicale associée à un substitut nicotinique versus substitut nicotinique seul sur le craving lié au sevrage tabagique
- Stéphane GUETIN, Music Care - Le soin par la musique : Music Care© un dispositif médical innovant dans la domaine de la prévention
16:50 - 18:30 : Plenary session and session Axe 4
- Aging & stem cells
Chair: Eric JULIEN
- KEYNOTE SPEAKER Clemens SCHMITT, Johannes Kepler University (Linz, Austria), Max-Delbrück-Center for Molecular Medicine and Molecular Cancer Research Center (MKFZ), Charité - Universitätsmedizin (Berlin, Germany) - Cancerstemflammaging – state/fate impact of cancer cell senescence
- Jean-Marc LEMAITRE, Institute for Regenerative Medicine and Biotherapy (IRMB), Montpellier - A single short reprogramming early in life improves fitness and increases lifespan in old age
- KEYNOTE SPEAKER Maël LEMOINE, ImmunoConcEpt (Bordeaux) - Stem cells, aging & cancer across species
- Nouveaux dispositifs numériques de dépistage / session Axe 4 diapositives
Modération: Florence SORDES
- Marie POISEUIL, Bordeaux Population Health, Dépist&vous
- Nadim FARES, CHU Toulouse, Predict-O: Projet d'Evaluation personnalisée du risque et Dépistage Individualisé du Cancer - TOulouse
18:30 - 19:15 :
- Prestige conference
Chairs:
- KEYNOTE SPEAKER Frédéric THOMAS, Infectious diseases and vectors: ecology, genetics, evolution and control (MIVEGEC, UMR 5290), Montpellier - Evolution & Cancer
Friday 2nd December
08:30 - 10:00 : Parallel sessions organized by Cancéropôle GSO Axes
- Cell signaling & Therapeutic targets / Axis 1 session
Chairs: Violaine MOREAU & Guillaume BOSSIS
- KEYNOTE SPEAKER Célio POUPONNOT, Curie Institute (Orsay) - EIF2A represents the central node of UPR-mediated cell death in high-risk medulloblastoma
- Olivier CALVAYRAC, Cancer Research Center of Toulouse (CRCT), Toulouse - Farnesyltransferase inhibition overcomes the adaptive resistance to targeted therapy in lung cancer
- Thomas BESSEDE, Montpellier Cancer Research Institute (IRCM), Montpellier - Sensitizing the tumor microenvironment to immune checkpoint therapy trough monoclonal antibody-based therapeutic combinations in pancreatic cancer
- Loélia BABIN, Cancer Research Center of Toulouse (CRCT), Toulouse - De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells
- Frédéric LAGARRIGUE, Institute of Pharmacology and Structural Biology (IPBS), Toulouse - Towards new approaches to target integrins in immune cells: the case of tumor-associated macrophages
- Radiotherapy & resistance / Axis 3 session
Chairs: Sandrine DABERNAT & Véronique VENDRELY
- KEYNOTE SPEAKER Jean BOURHIS, Lausanne University Hospital and Lausanne University, (Switzerland) - Flash Radiotherapy
- Véronique VENDRELY, Bordeaux Institute of Oncology (BRIC), Bordeaux - Radiosensitization of digestive tumors by bioactive food components
- Jean-Pierre POUGET, Montpellier Cancer Research Institute (IRCM), Montpellier - Role of extracellular vesicles during bystander cytotoxicity and bystander immunity of Targeted radionuclide therapy
- Elizabeth COHEN-JONATHAN MOYAL, Cancer Research Center of Toulouse (CRCT), Toulouse - Glioblastoma heterogeneity : a model for resistance
- Nouveaux dispositifs numériques de prise en charge / session Axe 4 diapositives
Modération: Silviane DARQUY
- Rémi IZOULET, CHU Toulouse - Un robot d’assistance sociale auprès d’enfants hospitalisés en isolement protecteur
- Hélène BUCHE, laboratoire Epsylon, La réalité virtuelle : un outil de soutien pertinent dans la relation de soins en chimiothérapie ?
- Clément SICARD, Thess Corporate, Thess : Dispositif de sécurisation et délivrance des traitements oraux
11:00 - 11:15 :
- Institut National du Cancer conference
11:15 - 12:45: Plenary session
- Urological cancers
Chair: Nadine HOUEDE
- KEYNOTE SPEAKER Andrea ALIMONTI, ETH Zurich (Switzerland) - Novel drivers of castration-resistant prostate cancer
- Guilhem ROUBAUD, Bergonié Institute (Bordeaux) - Prostate cancers and immunotherapies : hot or cold tumors?
- Philippe POURQUIER, Cancer Research Institute of Montpellier (IRCM), Montpellier - The role of PXR (Pregnane X receptor) and drug metabolism in the resistance of castration-resistant prostate cancers to kinase inhibitors
- Delphine MILHAS, Institute of Pharmacology and Structural Biology (IPBS), Toulouse - Collagen remodeling leads to inflammation-free expansion of periprostatic adipose tissue and promotes prostate cancer progression
- Fatima ALHOURANI, Montpellier Cancer Research Institute (IRCM), Montpellier - Molecular characterization of the combined chemotherapy of SUV4-20h epigenetic enzymes inhibitor with Topoisomerase II poisons in metastatic prostate cancer
